Patents by Inventor Gabor Rubanyi

Gabor Rubanyi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACID BASED CARDIOVASCULAR THERAPEUTICS
    Publication number: 20160296674
    Abstract: The present invention relates to methods and compositions for delivering a nucleic acid to be expressed in the myocardium of a patient. More specifically, the present invention relates to techniques and polynucleotide constructs for treating heart disease by in vivo delivery of angiogenic transgenes.
    Type: Application
    Filed: April 9, 2015
    Publication date: October 13, 2016
    Inventor: Gabor Rubanyi
  • NUCLEIC ACID BASED CARDIOVASCULAR THERAPEUTICS
    Publication number: 20130096500
    Abstract: The present invention relates to methods and compositions for delivering a nucleic acid to be expressed in the myocardium of a patient. More specifically, the present invention relates to techniques and polynucleotide constructs for treating heart disease by in vivo delivery of angiogenic transgenes.
    Type: Application
    Filed: July 9, 2012
    Publication date: April 18, 2013
    Inventor: Gabor Rubanyi
  • SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
    Publication number: 20090247521
    Abstract: The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.
    Type: Application
    Filed: December 23, 2008
    Publication date: October 1, 2009
    Inventors: Bhasker R. Aavula, Sampath-Kumar Anandan, Richard D. Gless, JR., Dinesh Patel, Gabor Rubanyi, Yi-Xin Wang, Heather K. Webb Hsu
  • Gene therapy for critical limb ischemia with wild type or mutant eNOS
    Publication number: 20040120930
    Abstract: The present invention provides novel methods of preventing, diagnosing, and treating Critical Limb Ischemia (CLI), using eNOS polypeptides and polynucleotides to modulate eNOS activity in cells. Wild-type and mutant eNOS polypeptides, and polynucleotides encoding such polypeptides, are provided for use in the methods of the present invention. The eNOS mutant polypeptides of the present invention have at least one mutation corresponding to a site in a functional domain of a mammalian eNOS that is phosphorylated in cells.
    Type: Application
    Filed: August 15, 2003
    Publication date: June 24, 2004
    Applicant: Schering Aktiengesellschaft
    Inventors: William P. Dole, Katalin Kauser, Hu Sheng Qian, Gabor Rubanyi
  • 17-difluoromethylene-estratrienes
    Patent number: 6018062
    Abstract: This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group,R.sup.5 means a methyl or ethyl group, andR.sup.2 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position,R.sup.3 means a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position,R.sup.4 means a hydrogen atom in .alpha.- or .beta.-position, andA, B, D, E and G each mean a hydrogen atom, and optionally at least one of substituent pairsG and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E mean a double bond.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: January 25, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Rolf Bohlmann, Gabor Rubanyi